PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1733.2040-001	10/681,571	
July 19, 2004	FIRST NAMED INVENTOR	FILING DATE	
(Use several sheets if necessary)	James R. Dasch	October 8, 2003	
	EXAMINER	CONFIRMATION NO.	GROUP
	Not yet assigned	9229	1646

OIPE JUL 21 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,700,485	12-23-1997	Berde *et al.*
	AB	6,214,387 B1	04-10-2001	Berde *et al.*
	AC	5,922,340	07-13-1999	Berde *et al.*
	AD	6,046,187	04-04-2000	Berde *et al.*
	AE	6,238,702 B1	05-29-2001	Berde *et al.*
	AF	6,426,339 B1	07-30-2002	Berde *et al.*
	AG	6,203,813 B1	03-20-2001	Gooberman
	AH	6,024,983	02-15-2000	Tice *et al.*
	AI	4,530,840	07-23-1985	Tice *et al.*
	AJ	4,542,025	09-17-1985	Tice *et al.*
	AK	5,618,563	04-08-1997	Berde *et al.*
	AA2	6,248,345 B1	06-19-2001	Goldenheim *et al.*

EXAMINER	DATE CONSIDERED
	7/07

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;465874;1

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1733.2040-001	10/681,571	
July 19, 2004	FIRST NAMED INVENTOR	FILING DATE	
(Use several sheets if necessary)	James R. Dasch	October 8, 2003	
	EXAMINER	CONFIRMATION NO.	GROUP
	Not yet assigned	9229	1646

OIPE JC156 JUL 21 2004 PATENT & TRADEMARK OFFICE

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AR	Weiss, J.M., *et al.*, "Osteopontin is Involved in the Initiation of Cutaneous Contact Hypersensitivity by Inducing Langerhans and Dendritic Cell Migration to Lymph Nodes," *J. Exp. Med.*, 194(9): 1219-1229 (2001).
	AS	Sansoni, P., *et al.*, "Inhibition of Antigen-Presenting Cell Function by Alendronate *In Vitro*," *J. Bone and Miner. Res.*, 10(11):1719-25 (1995).
	AT	Selander, K.S., *et al.*, "Characteristics of Clodronate-Induced Apoptosis in Osteoclasts and Macrophages" *Mol. Pharmacol.*, 50(5):1127-38 (1996).
	AU	Drucker, D.J., "Glucagon-Like Peptides," *Diabetes*, 47:159-69 (1998).
	AV	Renn, S.C.P., *et al.*, "Characterization and Cloning of Tripeptidyl Peptidase II from the Fruit Fly, *Drosophila melanogaster*," *J. Biol. Chem.*, 273(30):19173-82 (1998).
	AW	Spilizewski, K.L. *et al.*, "The Effect of Hydrocortisone Acetate Loaded Poly (DL-Lactide) Films on the Inflammatory Response," *Journal of Controlled Release*, 2: 197-203 (1985).
	AX	Zignani, M., *et al.*, "A Poly(ortho ester) Designed for Combined Ocular Delivery of Dexamethasone Sodium Phosphate and 5-Fluorouracil: Subconjunctival Tolerance and *In Vitro* Release," *European Journal of Pharmaceutics and Biopharmaceutics*, 50: 251-255 (2000).

EXAMINER	DATE CONSIDERED
	4/07

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	1733.2040-001	10/681,571	
	FIRST NAMED INVENTOR	FILING DATE	
	James R. Dasch	October 8, 2003	
May 24, 2005	EXAMINER	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)	Not yet assigned	9229	1646

PTO JC37 MAY 26 2005 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AB2	5,019,400	05-28-1991	Gombotz *et al.*

EXAMINER	DATE CONSIDERED
	4/07

MAR. 0 9 2007
PATENT & TRADEMARK OFFICE

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/681,571-Conf. #9229
Filing Date	October 8, 2003
First Named Inventor	James Dasch
Art Unit	1616
Examiner Name	E. J. Webman
Attorney Docket Number	000166.2040-US01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	BA	AU-AU-B-81544/94	07-11-1996	University of Miami		√
	BB	WO-WO 96/34599-A1	11-07-1996	Childrens Medical Center Corporation		√
	BC	WO-WO 97/44016-A1	11-27-1997	Samyang Corporation		√
	BD	WO-WO 99/01114-A1	01-14-1999	Euro-Celtique, S.A.		√
	BE	EP-EP 1 142 567-A2	10-10-2001	Takeda Chemical Industries, Ltd.		√

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [2] Applicant's unique citation designation number (optional). [3] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [4] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [5] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [6] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [7] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	